Evaxion announces new data showing its AML vaccine candidate, EVX-04, triggers strong T-cell responses and prevents tumor growth in preclinical models. The vaccine targets non-conventional ERV tumor antigens and is designed for acute myeloid leukemia (AML), a disease with high mortality rates. EVX-04 is an off-the-shelf therapeutic cancer vaccine with potential for other hard-to-treat cancers. The AI-Immunology™ platform identified 16 optimal sets of ERV fragments for broad tumor coverage. AML is a common leukemia affecting older adults, with limited treatment options. EVX-04 offers hope for improving outcomes in AML patients.

Read more at GlobeNewswire: Evaxion presents new data for EVX-04, a cancer vaccine